Infinity Pharmaceuticals, Inc. (INFI) Bundle
A Brief History of Infinity Pharmaceuticals, Inc. (INFI)
Company Formation and Early Years
Infinity Pharmaceuticals, Inc. was founded in 2000 as a biotechnology company focused on discovering and developing small molecule drugs for the treatment of cancer. The company was established in Cambridge, Massachusetts, and was initially funded through a combination of venture capital and partnerships.
Initial Public Offering (IPO)
In 2007, Infinity Pharmaceuticals went public, raising approximately $86 million through its IPO. The company traded on the NASDAQ under the ticker symbol INFI.
Key Drug Development Milestones
Infinity has developed several drug candidates over the years, notably:
- IPI-926 – A small molecule inhibitor of the hedgehog signaling pathway, which entered clinical trials in 2010.
- IPI-549 – An immune-oncology drug targeting the PI3K pathway, which received Fast Track designation from the FDA in 2017.
- Duvelisib (trade name Copiktra) – Approved by the FDA in 2018 for the treatment of certain types of lymphomas.
Partnerships and Collaborations
Infinity has entered into various partnerships to enhance its research and development efforts:
- In 2010, Infinity entered into a collaboration with AbbVie Inc. focusing on the development of drugs for cancer.
- In 2015, a partnership was established with F. Hoffmann-La Roche Ltd. to develop oncology drugs.
Financial Performance Overview
Infinity’s financial performance over the years has shown fluctuations in revenue and expenditure:
| Year | Revenue (in millions) | Net Income/Loss (in millions) | R&D Expenses (in millions) |
|---|---|---|---|
| 2018 | $41.4 | ($59.8) | $62.5 |
| 2019 | $19.6 | ($51.8) | $54.7 |
| 2020 | $34.0 | ($30.2) | $43.6 |
| 2021 | $15.7 | ($65.0) | $34.5 |
| 2022 | $29.9 | ($47.1) | $38.9 |
| 2023 (Q1) | $8.3 | ($10.2) | $7.8 |
Recent Developments and Future Outlook
As of 2023, Infinity Pharmaceuticals has been focusing on advancing its clinical pipeline, with emphasis on the treatment of various cancers. The company continues evaluating its financial strategy to optimize its resources and enhance shareholder value.
Stock Performance
The stock performance of Infinity Pharmaceuticals has seen significant volatility:
- IPO Price: $16 per share
- 2020 High: $33.85 per share
- 2020 Low: $2.93 per share
- 2023 Price Range: $0.93 to $1.52 per share
A Who Owns Infinity Pharmaceuticals, Inc. (INFI)
Current Ownership Structure
As of the latest data available in 2023, the ownership of Infinity Pharmaceuticals, Inc. (INFI) is distributed among institutional investors, retail investors, and company insiders. Below is a summary of these holdings:
| Type of Owner | Percentage of Ownership |
|---|---|
| Institutional Investors | 61.3% |
| Retail Investors | 24.5% |
| Insider Ownership | 14.2% |
Major Institutional Investors
Institutional investors hold a significant share of Infinity Pharmaceuticals. The following is a table highlighting the largest institutional shareholders:
| Investor Name | Shares Held | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 3,084,000 | 9.5% |
| The Vanguard Group, Inc. | 2,750,000 | 8.5% |
| Ariel Investments, LLC | 1,450,000 | 4.5% |
| State Street Global Advisors | 1,200,000 | 3.7% |
| Invesco Ltd. | 1,100,000 | 3.4% |
Insider Ownership
Insider ownership is a critical aspect of the company's governance. Below is a table showing key insiders of Infinity Pharmaceuticals and their corresponding shareholdings:
| Name | Position | Shares Held | Percentage of Ownership |
|---|---|---|---|
| Dr. Adelene Perkins | Chief Executive Officer | 1,200,000 | 3.7% |
| Dr. William J. Sullivan | Chief Scientific Officer | 800,000 | 2.5% |
| Darren C. J. Kahn | Chief Financial Officer | 300,000 | 0.9% |
| Board Members | Various | 500,000 | 1.6% |
Recent Share Performance and Market Capitalization
The market capitalization of Infinity Pharmaceuticals as of October 2023 is approximately $220 million, with shares trading at $3.10. The following table presents recent financial metrics:
| Metric | Value |
|---|---|
| Current Share Price | $3.10 |
| Market Capitalization | $220 million |
| 52-Week Range | $2.50 - $5.00 |
| Volume (Average) | 450,000 shares |
Recent Developments
In the past year, Infinity Pharmaceuticals has seen significant changes in their stock ownership and market performance:
- Announced strategic partnerships aimed at enhancing their drug pipeline.
- Received FDA approval for one of their experimental drugs, boosting investor confidence.
- Reported quarterly revenues of $5 million, reflecting a 20% increase year-over-year.
Infinity Pharmaceuticals, Inc. (INFI) Mission Statement
Overview
Infinity Pharmaceuticals, Inc. is committed to leveraging its innovative science and drug discovery to develop breakthrough treatments for patients battling cancer. The company focuses on advancing precision medicines to improve patient outcomes and quality of life.
Mission Statement
Infinity Pharmaceuticals aims to transform the treatment landscape for patients with cancer through innovative therapies that target the underlying mechanisms of disease.
Core Values
- Innovation: Continuous pursuit of novel scientific approaches.
- Excellence: Commitment to high standards in research and development.
- Collaboration: Building partnerships to enhance research capabilities.
- Patient-Centricity: Focus on the needs and well-being of patients.
- Integrity: Upholding ethical standards in all operations.
Financial Overview
As of the most recent quarterly report in Q3 2023, Infinity Pharmaceuticals reported the following financial statistics:
| Metric | Value |
|---|---|
| Total Revenue | $5.3 million |
| Net Loss | $14.2 million |
| Cash and Cash Equivalents | $50 million |
| Research and Development Expense | $10 million |
| General and Administrative Expense | $4 million |
| Market Capitalization | $200 million |
| Stock Price (as of October 20, 2023) | $2.15 |
Strategic Goals
The strategic goals set forth by Infinity Pharmaceuticals include:
- Advancing clinical candidates to late-stage trials.
- Exploring potential partnerships with biotechnology firms.
- Increasing investment in research and development to enhance pipeline diversity.
- Expanding market access for current and future products.
- Enhancing operational efficiency to optimize resources.
Key Products in Development
The following products are key components of Infinity Pharmaceuticals' pipeline:
| Product Name | Indication | Phase of Development |
|---|---|---|
| Duvelisib | Chronic lymphocytic leukemia (CLL) | Phase 3 |
| IPI-549 | Solid tumors | Phase 2 |
| Infinity-1 | Ovarian cancer | Phase 1 |
Patient Engagement Initiatives
Infinity Pharmaceuticals is dedicated to engaging with patients through various initiatives:
- Patient advisory boards to gather insights.
- Educational programs on treatment options.
- Support groups to enhance patient experience.
- Surveys to assess patient needs and satisfaction.
Recent Achievements
Recent milestones include:
- Positive results from Phase 2 trials of IPI-549.
- Strategic alliance formed with a leading oncology research institute.
- Recognition for innovation in cancer research at the 2023 Oncology Conference.
Conclusion
This chapter encapsulates the mission, values, financial health, strategic direction, and ongoing initiatives of Infinity Pharmaceuticals, Inc. as it strives to make a significant impact in the field of oncology.
How Infinity Pharmaceuticals, Inc. (INFI) Works
Company Overview
Company Overview
Infinity Pharmaceuticals, Inc. (INFI) is a biotechnology company focused on the discovery and development of innovative medicines for cancer treatment. As of the end of Q3 2023, the company had a market capitalization of approximately $140 million.
Key Products and Pipeline
Infinity has several product candidates in its pipeline. The most notable is IPI-549, a phosphoinositide-3-kinase (PI3K) inhibitor targeted at various cancers. The status of IPI-549 is as follows:
| Product Candidate | Indication | Phase | Expected Milestone |
|---|---|---|---|
| IPI-549 | Solid Tumors | Phase 2 | Data Readout Q4 2023 |
| IPI-549 + Nivolumab | Metastatic Melanoma | Phase 1/2 | Data Readout Q1 2024 |
| IPI-926 | Multiple Solid Tumors | Phase 1 | Enrollment Completion Q2 2024 |
Financial Performance
For the third quarter of fiscal year 2023, Infinity reported financial results as follows:
| Financial Metric | Q3 2023 | Q2 2023 | Year-over-Year Change |
|---|---|---|---|
| Total Revenue | $5 million | $4.2 million | +19% |
| Net Loss | ($12 million) | ($10 million) | -20% |
| Cash and Cash Equivalents | $30 million | $25 million | +20% |
| Expense Ratio | 240% | 238% | +2% |
Research and Development
Research and Development (R&D) is a major focus for Infinity Pharmaceuticals. The company allocated approximately 75% of its total expenses to R&D in Q3 2023. The breakdown is as follows:
| Expense Type | Amount (Q3 2023) | Percentage of Total Expenses |
|---|---|---|
| Clinical Trials | $7 million | 58% |
| Preclinical Studies | $2 million | 17% |
| Product Development | $1 million | 8% |
| Other R&D Expenses | $2 million | 17% |
Collaboration and Partnerships
Infinity has formed several strategic partnerships to enhance its R&D capabilities. These collaborations include:
- Alliance with AbbVie for joint development programs.
- Collaboration with Merck for combination therapy studies.
- Partnership with the National Cancer Institute for expansive clinical trials.
Market Strategy
Infinity Pharmaceuticals focuses on niche oncology markets with unmet medical needs. Their marketing strategy emphasizes:
- Identification of biomarkers for targeted therapy.
- Engagement with oncologists through educational initiatives.
- Participation in major oncology conferences to showcase research findings.
Current Challenges
Infinity faces several challenges in the competitive biotechnology landscape:
- Regulatory hurdles in drug approval processes.
- Competition from larger pharmaceutical companies.
- The need for continuous funding to support clinical trials.
How Infinity Pharmaceuticals, Inc. (INFI) Makes Money
Revenue Sources
Infinity Pharmaceuticals, Inc. primarily generates revenue through the development and commercialization of innovative drugs. Its financial performance can be categorized into the following sources:
- Product Revenue: Revenue derived from the sales of approved pharmaceuticals.
- Collaborative Revenue: Revenue from partnerships with larger pharmaceutical companies for drug development and commercialization.
- Grants and Other Income: Financial support from government or private entities for research and development initiatives.
Product Revenue
As of the latest financial report, Infinity Pharmaceuticals has one significant product on the market, MARQIBO (Vincristine sulfate liposome injection), which is used in treating certain types of leukemia.
Product revenue for MARQIBO amounted to approximately $15 million for the fiscal year 2022.
Collaborative Revenue
Infinity has established collaborative agreements with other pharmaceutical entities, which provide significant revenue through milestone payments and royalties. Recent collaborations include:
| Partner | Type of Agreement | Upfront Payment | Potential Milestone Payments | Royalty Rate |
|---|---|---|---|---|
| AbbVie | Collaboration for IPI-549 | $20 million | $135 million | Up to 20% |
| Almirall | Licensing Agreement | $10 million | $50 million | Up to 15% |
Grants and Other Income
In addition to product and collaborative revenues, Infinity Pharmaceuticals has received various grants to support its research efforts. In fiscal year 2022, the company reported $5 million in grant revenue from the National Institutes of Health (NIH) for the development of novel cancer therapies.
Financial Performance and Outlook
Infinity's financial results for the fiscal year ending December 31, 2022, are as follows:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $30 million |
| Net Loss | $(45 million) |
| R&D Expenses | $35 million |
| Cash and Cash Equivalents | $50 million |
Infinity Pharmaceuticals continues to invest heavily in research and development, underscoring its commitment to innovation in cancer therapeutics.
Market Opportunities
The company is poised to capitalize on emerging market opportunities with its pipeline candidates, which include:
- IPI-549: A selective PI3K-gamma inhibitor currently in clinical trials for various cancers.
- IPI-943: A therapeutic agent targeting immune modulation.
With a strong pipeline of candidates, Infinity Pharmaceuticals aims to enhance its revenue through future product launches and collaborations.
Infinity Pharmaceuticals, Inc. (INFI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support